Table 2: Metabolic parameters of the study groups.
|
Control n: 31 |
Type 1 DM n: 64 |
Type 2 DM n: 67 |
p |
Significant within group differences |
Betatrophin(ng/l) |
106.19 ± 59.07 |
322.73 ± 366.05 |
144.84 ± 124.50 |
0.000a |
Type 1 DM >Controle Type 1 DM >Type 2 DMe |
C-peptide(ng/ml) |
1.16 ± 0.69 |
0.56 ± 0.34 |
1.34 ± 0.78 |
0.000a |
Type 1 DM <Controle Type 2 DM >Type 1 DMe |
GFR(ml/dak -1.73m2) |
115.30 ± 25.31 |
111.07 ± 27.96 |
91.33 ± 41.66 |
0.000a |
Type 2 DM <Controle Type 2 DM <Type 1 DMe |
Microalbuminuria (mg/g) |
38.69 ± 115.05 |
129.50 ± 318.09 |
139.55 ± 298.86 |
0.010a |
Type 1 DM >Controle Type 2 DM >Controle |
Total C)(mg/dl) |
202.55 ± 43.74 |
190.56 ± 51.46 |
211.27 ± 44.90 |
0.046b |
Type 2 DM >Type 1 DMd |
Triglyceride (mg/dl) |
135.77 ± 76.98 |
179.97 ± 194.20 |
196.45 ± 133.29 |
0.022a |
Type 2 DM >Controle |
HDL-C(mg/dl) |
45.65 ± 10.02 |
45.95 ± 15.17 |
46.75 ± 16.08 |
0.895a |
N/A |
LDL-C(mg/dl) |
122.81 ± 33.57 |
114.56 ± 35.38 |
131.46 ± 39.80 |
0.037b |
Type 2 DM >Type 1 DMd |
FBG(mg/dl) |
84.58 ± 12.91 |
151.86 ± 57.33 |
162.17 ± 43.76 |
0.000a |
Type 1 DM >Controle Type 2 DM >Controle Type 2 DM >Type 1 DMe |
Insulin(qU/ml) |
7.02 ± 1.19 |
4.48 ± 2.21 |
7.22 ± 3.04 |
0.000a |
Type 1 DM <Controle Type 2 DM >Type 1 DMe |
Albumin(g/dl) |
4.28 ± 0.26 |
4.23 ± 0.39 |
4.24 ± 0.33 |
0.961a |
N/A |
CRP(mg/dl) |
0.67 ± 0.50 |
0.58 ± 0.43 |
0.81 ± 1.49 |
0.714a |
N/A |
HbA1c(%) |
6.38 ± 1.09 |
8.71 ± 2.11 |
8.49 ± 2.02 |
0.000b |
Type 2 DM > Controld Type 1 DM > Controld |
Kruskal Wallis H Test, b. One Way ANOVA Test, d. Tukey Test, e. Mann Whitney U Test, N/A: Not Applicable
C-peptide: 0.8-3.85 ng/ml, GFR>110 ml/dk/1.73m2, microalbuminuri: 30-300 mg/dl, T-cholesterol < 200mg/dl, triglyceride < 150 mg/dl, LDL-C < 130 mg/dl, HDL-C: 40-60 mg/dl, FBG: 70-95 mg/dl, insulin: 1.923 qU/ml, albumin: 3.5 g/dl, CRP: 0-5 mg/dl, HbA1c: 6.5 %